Key facts
- GreenLight Biosciences’s last known valuation is $45.5M (Jul 2023).
- It has raised $61.7M across 5 recorded rounds; the latest was Later Stage VC ($102.5M) in Jun 2020.
- Notable investors include Fall Line Capital, Just Climate.
- GreenLight Biosciences has filed 6 Form Ds with the SEC since 2013, most recently Jun 2020 ($102.5M sold to 19 investors).
- Status: Acquired/Merged (Operating Subsidiary).
Investors
2- ·Post-money valuations for all 5 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for GreenLight Biosciences
Funding rounds
5 roundsAbout GreenLight Biosciences
Developer of sustainable crop protection technology using Ribonucleic Acid (RNA) designed to be economically produced through a proprietary cell-free production platform. The company offers RNA-based products for plant and life science applications, including crop management, plant protection, and animal health, enabling farmers and researchers to protect crops and livestock in an environmentally responsible way.
- Sector
- Healthcare
- HQ
- Medford, MA, United States
- Founded
- 2008
- Employees
- 188
- Website
- greenlightbiosciences.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
GreenLight Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GreenLight Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GreenLight Biosciences in its N-PORT filings yet. We sweep new filings monthly.